New cocktail of drugs shows promise against tough bile duct cancer
NCT ID NCT05451290
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of immunotherapy (camrelizumab), a targeted therapy (apatinib), and chemotherapy (gemcitabine and oxaliplatin) given before and after surgery for 30 people with advanced biliary tract cancer. The goal is to see if this approach can shrink tumors enough for successful removal and delay cancer return. Participants will also take a maintenance drug (tegafur) for up to a year after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab, apatinib, gemcitabine, oxaliplatin, and tegafur
What this could lead to
If successful, this combination could help shrink tumors before surgery and prevent recurrence afterward, potentially improving survival for people with advanced biliary tract cancer.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination can cause serious side effects, and it's not yet proven to be better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China